2018
DOI: 10.34071/jmp.2018.3.8
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy and Side Effects of R-Chop Regimen in Patients With Diffuse Large B-Cell Cd20 Positive Lymphoma at Hue University of Medicine and Pharmacy Hospital

Abstract: Background: Non-Hodgkin lymphomas (NHL) ranks 10 among the top 15 common cancers worldwide. Diffuse large B-cell lymphoma (DLBCL) is the most common type of the disease. Despite malignancy, DLBCL is curable and sensitive to chemotherapy and radiation therapy. Since first published in 1997, the protocol R-CHOP, a combination of classical chemotherapy CHOP with rituximab, has increased significantly the rate of complete response (CR) and improved overall survival (OS). However, there has been no report of R-CHOP… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2020
2020
2020
2020

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
references
References 14 publications
0
0
0
Order By: Relevance